Five-year subgroup analysis of tafasitamab plus lenalidomide from the phase II L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma

被引：0
|
作者：
Duell, Johannes
Abrisqueta, Pau
Dreyling, Martin H.
Gaidano, Gianluca
Barca, Eva Gonzalez
Jurczak, Wojciech
Maddocks, Kami J.
Menne, Tobias
Tournilhac, Olivier
Bakuli, Abhishek
Amin, Aasim
Gurbanov, Konstantin
Salles, Gilles A.
Nagy, Zsolt
机构：
[1] Univ Klin Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[2] Vall Hebron Univ Hosp, Dept Hematol, Vall Hebron Inst Oncol VHIO, Barcelona, Spain
[3] Ludwig Maximilians Univ Hosp, Munich, Germany
[4] Univ Piemonte Orientale, Div Hematol, Dept Translat Med, Novara, Italy
[5] Univ Barcelona, Inst Catal Oncol, Hosp Duran Reynals, IDIBELL, Barcelona, Spain
[6] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Clin Oncol, Krakow, Poland
[7] Ohio State Univ Wexner Med Ctr, Dept Internal Med, Arthur G James Comprehens Canc Ctr, Columbus, OH USA
[8] Newcastle Tyne Hosp, Freeman Hosp, Newcastle Upon Tyne, Tyne & Wear, England
[9] CHU Clermont Ferrand, Clermont Ferrand, France
[10] MorphoSys AG, Planegg, Germany
[11] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[12] Semmelweis Univ, Budapest, Hungary
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19522
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Subgroup analysis in RE-MIND2, an observational, retrospective cohort study of tafasitamab plus lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
    Nowakowski, Grzegorz S.
    Yoon, Dok Hyun
    Joffe, Erel
    Zinzani, Pier Luigi
    Sabatelli, Lorenzo
    Waltl, Eva E.
    Alvero, Carmelita G.
    Hess, Georg
    Riedell, Peter A.
    Kim, Kibum
    Brixner, Diana
    Salles, Gilles A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] L-MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R-R DLBCL)-A SINGLE-ARM PHASE II STUDY
    Maddocks, K.
    Gonzalez Barca, E.
    Jurczak, W.
    Liberati, A. M.
    Duell, J.
    Nagy, Z.
    Papaj-K, T.
    Andre, M.
    Kalakonda, N.
    Dreyling, M.
    Zinzani, P. L.
    Ambarkhane, S.
    Weirather, J.
    Salles, G.
    HAEMATOLOGICA, 2017, 102 : 174 - 174
  • [33] L-MIND: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R-R DLBCL) - a single-arm phase II study
    Duell, J.
    Gonzalez Barca, E.
    Liberati, A. M.
    Salles, G.
    Gaidano, G.
    Jurczak, W.
    Nagy, Z.
    Papajlk, T.
    Andre, M.
    Zinzani, P. L.
    Kalakonda, N.
    Ambarkhane, S.
    Weirather, J.
    Maddocks, K.
    Dreyling, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 68 - 68
  • [34] Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Ohmachi, Ken
    Niitsu, Nozomi
    Uchida, Toshiki
    Kim, Seok Jin
    Ando, Kiyoshi
    Takahashi, Naoki
    Takahashi, Naoto
    Uike, Naokuni
    Eom, Hyeon Seok
    Chae, Yee Soo
    Terauchi, Takashi
    Tateishi, Ukihide
    Tatsumi, Mitsuaki
    Kim, Won Seog
    Tobinai, Kensei
    Suh, Cheolwon
    Ogura, Michinori
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (17) : 2103 - +
  • [35] L-mind: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large b-cell lymphoma (R-R DLBCL)-A single-arm phase II study.
    Maddocks, Kami J.
    Barca, Eva Gonzalez
    Jurczak, Wojciech
    Liberati, Anna Marina
    Duell, Johannes
    Nagy, Zsolt
    Papajik, Tomas
    Andre, Marc
    Kalakonda, Nagesh
    Dreyling, Martin H.
    Zinzani, Pier Luigi
    Ambarkhane, Sumeet Vijay
    Weirather, Johannes
    Salles, Gilles A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] COST-EFFECTIVENESS ANALYSIS OF TAFASITAMAB IN COMBINATION WITH LENALIDOMIDE FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN GREECE
    Karaiskou, M.
    Avgitidou, A.
    Vostitsanou, Z.
    Batsi, M.
    Bungey, G.
    Prawitz, T.
    Peter, B.
    Stafylas, P.
    VALUE IN HEALTH, 2023, 26 (12) : S151 - S151
  • [37] Positive CHMP Opinion on Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with relapsed or refractory diffuse large B-cell Lymphoma
    不详
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2021, 48 (04) : 263 - 263
  • [38] The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
    Delgado, Julio
    Papadouli, Irene
    Sarac, Sinan B.
    Moreau, Alexandre
    Hovgaard, Doris
    Gisselbrecht, Christian
    Enzmann, Harald
    Pignatti, Francesco
    HEMASPHERE, 2021, 5 (12): : E666
  • [39] Efficacy and safety of lenalidomide in relapsed/refractory diffuse large B-cell lymphoma
    Habermann, T.
    Lossos, I.
    Justice, G.
    Tuscano, J.
    Cole, C.
    Vose, J.
    Pietronigro, D.
    Takeshita, K.
    Ervin-Haynes, A.
    Zeldis, J.
    Wiernik, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 150 - 150
  • [40] Subcutaneous Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma from EPCORE NHL-5
    Mazza, Irit Avivi
    Kim, Won Seog
    Ko, Shen
    Grande, Carlos
    Lavie, David
    Chism, David
    Seliem, Mostafa
    Jeng, Edwin E.
    Joshi, Neha
    Siddani, Satya
    Assaily, Wissam
    Sacchi, Mariana
    Dinh, Minh
    Avigdor, Abraham
    BLOOD, 2023, 142
12345